Articles related to BLOOD DISORDERS
Four Groundbreaking Clinical Studies Worth Your Attention
A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.
Cardiology September 20th 2022
Cases in the Management of Polycythemia Vera: The Importance of Strict Hematocrit Control
Memorial Sloan Kettering oncologist Raajit Rampal presents a case report, discusses the rationale for the few treatment options available, and summarizes the 5-year follow-up data for the RESPONSE and RESPONSE 2 trials.
Hematology August 8th 2022
Cases in the Management of Polycythemia Vera: Switching From Hydroxyurea to Ruxolitinib to Resolve Symptoms and Improve Quality of Life
In this first part of a three-case series, a 65-year-old man received ruxolitinib for treatment and reported feeling much better after one month, and after two months of treatment, most of his symptoms had completely resolved and his blood cell counts were maintained under control.
Hematology July 5th 2022
The Devil is in the Details: Approach to Refractory Hypokalemia
Follow this case study of a 71-year-old man found to have significant, asymptomatic hypokalemia discovered in routine outpatient lab work. How would you manage this patient?
Cardiology April 19th 2022
Complement and the Prothrombotic State
Parallels and distinct features among paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are discussed against the background of thrombosis, complement activation via eculizumab, and potential complement diagnostic and therapeutic avenues.
Hematology April 5th 2022